Literature DB >> 25950141

Experimental hepatocyte xenotransplantation--a comprehensive review of the literature.

Huidong Zhou1,2, Hong Liu1,3, Mohamed Ezzelarab1, Eva Schmelzer4, Yi Wang2, Jörg Gerlach4, Bruno Gridelli5, David K C Cooper1.   

Abstract

Hepatocyte transplantation (Tx) is a potential therapy for certain diseases of the liver, including hepatic failure. However, there is a limited supply of human livers as a source of cells and, after isolation, human hepatocytes can be difficult to expand in culture, limiting the number available for Tx. Hepatocytes from other species, for example, the pig, have therefore emerged as a potential alternative source. We searched the literature through the end of 2014 to assess the current status of experimental research into hepatocyte xenoTx. The literature search identified 51 reports of in vivo cross-species Tx of hepatocytes in a variety of experimental models. Most studies investigated the Tx of human (n = 23) or pig (n = 19) hepatocytes. No studies explored hepatocytes from genetically engineered pigs. The spleen was the most common site of Tx (n = 23), followed by the liver (through the portal vein [n = 6]) and peritoneal cavity (n = 19). In 47 studies (92%), there was evidence of hepatocyte engraftment and function across a species barrier. The data provided by this literature search strengthen the hypothesis that xenoTx of hepatocytes is feasible and potentially successful as a clinical therapy for certain liver diseases, including hepatic failure. By excluding vascular structures, hepatocytes isolated from genetically engineered pig livers may address some of the immunological problems of xenoTx.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  hepatocytes; pig; xenotransplantation

Mesh:

Year:  2015        PMID: 25950141      PMCID: PMC4519403          DOI: 10.1111/xen.12170

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  132 in total

1.  Hepatocyte transplantation as a treatment for glycogen storage disease type 1a.

Authors:  Maurizio Muraca; Giorgio Gerunda; Daniele Neri; Maria-Teresa Vilei; Anna Granato; Paolo Feltracco; Muzio Meroni; Gianpiero Giron; Alberto B Burlina
Journal:  Lancet       Date:  2002-01-26       Impact factor: 79.321

2.  Interspecies difference in liver-specific functions and biotransformation of testosterone of primary rat, porcine and human hepatocyte in an organotypical sandwich culture.

Authors:  Angelika Langsch; Shibashish Giri; Ali Acikgöz; Inka Jasmund; Bernd Frericks; Augustinus Bader
Journal:  Toxicol Lett       Date:  2009-04-02       Impact factor: 4.372

3.  Treatment of acute liver failure in mice by hepatocyte xenotransplantation.

Authors:  Tsuyoshi Yamamoto; Nalú Navarro-Alvarez; Alejandro Soto-Gutierrez; Takeshi Yuasa; Masaya Iwamuro; Yasuhiro Kubota; Masayuki Seita; Hironobu Kawamoto; Shahid M Javed; Eisaku Kondo; Hirofumi Noguchi; Satoru Kobayashi; Shuhei Nakaji; Naoya Kobayashi
Journal:  Cell Transplant       Date:  2010-06-23       Impact factor: 4.064

4.  Nonenzymatic versus enzymatic hepatocyte isolation from pig livers for larger scale investigations of liver cell perfusion systems.

Authors:  J C Gerlach; J Brombacher; J M Courtney; P Neuhaus
Journal:  Int J Artif Organs       Date:  1993-09       Impact factor: 1.595

5.  Life-supporting human complement regulator decay accelerating factor transgenic pig liver xenograft maintains the metabolic function and coagulation in the nonhuman primate for up to 8 days.

Authors:  P Ramirez; R Chavez; M Majado; V Munitiz; A Muñoz; Q Hernandez; C G Palenciano; G Pino-Chavez; M Loba; A Minguela; J Yelamos; M R Gago; A S Vizcaino; H Asensi; M G Cayuela; B Segura; F Marin; A Rubio; T Fuente; R Robles; F S Bueno; T Sansano; F Acosta; J M Rodriguez; F Navarro; J Cabezuelo; E Cozzi; D J White; R Y Calne; P Parrilla
Journal:  Transplantation       Date:  2000-10-15       Impact factor: 4.939

6.  Sustained engraftment and tissue enzyme activity after liver cell transplantation for argininosuccinate lyase deficiency.

Authors:  Xavier Stéphenne; Mustapha Najimi; Catherine Sibille; Marie-Cécile Nassogne; Françoise Smets; Etienne M Sokal
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

7.  Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up.

Authors:  Etienne M Sokal; Françoise Smets; Annick Bourgois; Lionel Van Maldergem; Jean-Paul Buts; Raymond Reding; Jean Bernard Otte; Veerle Evrard; Dominique Latinne; Marie Françoise Vincent; Anne Moser; Humberto E Soriano
Journal:  Transplantation       Date:  2003-08-27       Impact factor: 4.939

8.  One liver for four children: first clinical series of liver cell transplantation for severe neonatal urea cycle defects.

Authors:  Jochen Meyburg; Anibh M Das; Friederike Hoerster; Martin Lindner; Heinz Kriegbaum; Guido Engelmann; Jan Schmidt; Michael Ott; Andrea Pettenazzo; Thomas Luecke; Harald Bertram; Georg F Hoffmann; Alberto Burlina
Journal:  Transplantation       Date:  2009-03-15       Impact factor: 4.939

9.  Transplantation of reversibly immortalized insulin-secreting human hepatocytes controls diabetes in pancreatectomized pigs.

Authors:  Teru Okitsu; Naoya Kobayashi; Hee-Sook Jun; Seungjin Shin; Su-Jin Kim; Jaeseok Han; Hyokjoon Kwon; Masakiyo Sakaguchi; Toshinori Totsugawa; Michinori Kohara; Karen A Westerman; Noriaki Tanaka; Philippe Leboulch; Ji-Won Yoon
Journal:  Diabetes       Date:  2004-01       Impact factor: 9.461

10.  Clinical applications of hepatocyte transplantation.

Authors:  Giada Pietrosi; Giovanni Battista Vizzini; Salvatore Gruttadauria; Bruno Gridelli
Journal:  World J Gastroenterol       Date:  2009-05-07       Impact factor: 5.742

View more
  7 in total

1.  Transplantation of hepatocytes from genetically engineered pigs into baboons.

Authors:  Hayato Iwase; Hong Liu; Eva Schmelzer; Mohamed Ezzelarab; Martin Wijkstrom; Hidetaka Hara; Whayoung Lee; Jagjit Singh; Cassandra Long; Eric Lagasse; Jörg C Gerlach; David K C Cooper; Bruno Gridelli
Journal:  Xenotransplantation       Date:  2017-01-28       Impact factor: 3.907

Review 2.  Cell-based liver therapies: past, present and future.

Authors:  Valeria Iansante; Anil Chandrashekran; Anil Dhawan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-07-05       Impact factor: 6.237

Review 3.  Cell therapy in chronic liver disease.

Authors:  Clara T Nicolas; Yujia Wang; Scott L Nyberg
Journal:  Curr Opin Gastroenterol       Date:  2016-05       Impact factor: 3.287

4.  Synthetic liver function is detectable in transgenic porcine livers perfused with human blood.

Authors:  Arielle Cimeno; Beth M French; Jessica M Powell; Carol Phelps; David Ayares; Natalie A O'Neill; Christopher T Laird; Richard N Pierson; Agnes M Azimzadeh; Rolf N Barth; John C LaMattina
Journal:  Xenotransplantation       Date:  2017-10-25       Impact factor: 3.907

5.  Establishment of human hair follicle mesenchymal stem cells with overexpressed human hepatocyte growth factor.

Authors:  Dan Zhou; Hongjing Cheng; Jinyu Liu; Lei Zhang
Journal:  Iran J Basic Med Sci       Date:  2017-06       Impact factor: 2.699

Review 6.  Liver and Hepatocyte Transplantation: What Can Pigs Contribute?

Authors:  Xiaoxue Li; Ying Wang; Haiyuan Yang; Yifan Dai
Journal:  Front Immunol       Date:  2022-01-14       Impact factor: 7.561

Review 7.  Mesenchymal Stromal/Stem Cells and Their Extracellular Vesicles Application in Acute and Chronic Inflammatory Liver Diseases: Emphasizing on the Anti-Fibrotic and Immunomodulatory Mechanisms.

Authors:  Ali Hazrati; Kosar Malekpour; Sara Soudi; Seyed Mahmoud Hashemi
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.